The treatment and outcomes of diabetic macular oedema (DMO) have improved with the introduction of intravitreal injections. However, real-world data reveal that the burden of DMO treatment causes large gaps in outcomes between randomized clinical trials and daily clinical practice. Long-lasting intravitreal drugs and devices for DMO might reduce this disparity by achieving optimal treatment due to more feasible injection regimens. In this manuscript, we cover pharmacodynamics, preliminary results from clinical trials, and safety behavior about brolucizumab, faricimab, conbercept, KSI-301, and port-delivery system WR42221. These treatments might present the first step to control the global epidemic of diabetic eye disease in real life.
随着玻璃体腔内注射治疗药物的引入, 糖尿病性黄斑水肿 (DMO) 的治疗和预后得到了改善。然而, 真实数据显示, DMO治疗的负担导致随机临床试验和日常临床实践之间的结果存在巨大差距。DMO长效玻璃体腔内药物和装置可能通过更可行的注射方案实现最佳治疗, 从而减少这种差异。在这篇手稿中, 我们介绍了brolucizumab单抗、faricimab单抗、康柏西普、KSI-301和药物递送系统 WR42221的药效学、临床试验的初步结果及安全评估。这些治疗可能是现实生活中控制糖尿病眼病全球流行的第一步。
© 2021. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.